Securities code: Sailong Pharmaceutical Group Co.Ltd(002898) securities abbreviation: Sailong Pharmaceutical Group Co.Ltd(002898) Announcement No.: 2022007 Sailong Pharmaceutical Group Co.Ltd(002898)
Announcement on stock price changes
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Abnormal fluctuation of stock trading
Sailong Pharmaceutical Group Co.Ltd(002898) (hereinafter referred to as “the company” or “the company”), the stock of the company (Securities abbreviation: Sailong Pharmaceutical Group Co.Ltd(002898) , securities code: Sailong Pharmaceutical Group Co.Ltd(002898) ) deviated by 20.00% for three consecutive trading days on March 3, March 4 and March 7, 2022. According to the relevant regulations of Shenzhen stock exchange, it belongs to abnormal stock fluctuation.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s shares, the company checked the relevant matters and verified with the controlling shareholder and the actual controller that there is no material information that should be disclosed but not disclosed. The relevant information is explained as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage;
2. The company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
3. There has been no significant change in the company’s business situation and internal and external business environment recently;
4. After verification, the company, the controlling shareholder and the actual controller have no major matters that should be disclosed but not disclosed about the company, or are in the planning stage;
5. After verification, the controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the stock change period;
6. Through self-examination, the company has no other circumstances in violation of the provisions on fair information disclosure.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange or planning, negotiation, intention, agreement, etc. related to the matters; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Risk tips
1. After self-examination, the company does not violate the fair disclosure of information.
2. The company disclosed the 2021 annual performance forecast (Announcement No.: 2022006) on January 29, 2022. As of the disclosure date of this announcement, the above performance is not expected to be corrected. The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021. The undisclosed regular performance information of the company is not provided to any third party other than the accounting firm audited by the company.
3. The company solemnly reminds investors that the information disclosure media currently designated by the company are Shanghai Securities News, securities times, China Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. ）, all information of the company shall be subject to the information published in the above designated media.
The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks.
It is hereby announced.
Sailong Pharmaceutical Group Co.Ltd(002898) board of directors
March 8, 2022
